(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an orally-administered near-complete stabilizer of Transthyretin for the ...
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback